Soleus Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Soleus Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,700	Closed	-$235K	–	64
2019 Q4	$235K	Buy	+10,700	New	+$215K	0.23%	47

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Soleus Capital Management's DRNA Position: Q1 2020 in Review

Soleus Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020, closing a stake of 10,700 shares — an estimated $235K sold.

Soleus Capital Management first reported a position in DRNA in Q4 2019 and held it in 1 quarter. The position peaked at $235K in Q4 2019. 144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

Soleus Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Soleus Capital Management sold 10,700 Dicerna Pharmaceuticals, Inc. shares in Q1 2020, an estimated $235K.
Soleus Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
Soleus Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $235K in Q4 2019.
144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on Soleus Capital Management's 13F filing for Q1 2020, filed 15 May 2020.